Hemotune raises €14.3M Series B round

25 March 2024· Zurich, Switzerland· health, medtech, nanotechnology, biotech, magnetic_separation, b2b, software_hardware

The funding will advance its HemoSystem blood purification platform into clinical trials, initially focusing on treating sepsis-related immune suppression, and explore other potential uses for the platform.

Investors

LeadBelmondo

Also participating

Zürcher KantonalbankEFI Lake Geneva VenturesVP Venture PartnersHEMEXOCCIDENT

About Hemotune

Stage

Series B

Headquarters

Zurich, Switzerland

Founded

2017

Team Size

21–50

Sectors

healthmedtechnanotechnologybiotechmagnetic_separationb2bsoftware_hardware

https://www.hemotune.ch

Source: https://occident.group/news/hemotune-raises-chf-14-million-series-b2-funding-for-clinical-trials-with-their-disruptive-blood-purification-platform/, https://www.venturelab.swiss/hemotune-secures-chf-14-million-in-series-b2-funding-to-advance-innovative-blood-purification-technology/, https://startupticker.ch/en/news/hemotune-ag-raises-chf-14m-series-b2-funding-for-clinical-trials-with-the-hemosystem